When does this change take effect?

This change is effective May 28, 2025.

Back to dashboard

CommercialCoverageLow impact

08.02.21, ADAMTS13, recombinant-krhn (Adzynma)

Q: Who is affected by this change?

This affects Independence Blue Cross Hematology, Critical Care, Emergency Medicine providers on Commercial plans.

Independence Blue Cross·Hematology, Critical Care, Emergency Medicine·Medical Policy

Effective date

May 28, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a reissued commercial policy for ADAMTS13, recombinant-krhn (Adzynma), a specialized treatment for thrombotic thrombocytopenic purpura (TTP). The policy has been updated and will be reissued effective May 28, 2025.

Action Required

Action needed

By May 28, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage criteria or billing requirements for ADAMTS13, recombinant-krhn (Adzynma). This affects a rare blood disorder treatment, so impact will be minimal for most practices.

Related policy hubs

Independence Blue Cross policies Hematology Critical Care Emergency Medicine